IBS C News and Research

RSS

Actavis announces FDA approval of VIBERZI (eluxadoline) for IBS-D treatment

Actavis plc announced today that VIBERZI (eluxadoline) was approved by the Food and Drug Administration as a twice-daily, oral treatment for adults suffering from irritable bowel syndrome with diarrhea (IBS-D). VIBERZI (eluxadoline) has mixed opioid receptor activity, it is a mu receptor agonist, a delta receptor antagonist, and a kappa receptor agonist.

28 May 2015

Salix Pharmaceuticals receives FDA approval for Xifaxan 550 mg to treat IBS-D in adults

Valeant Pharmaceuticals International, Inc. announced that its wholly owned subsidiary, Salix Pharmaceuticals, Inc., has received approval from the U.S. Food and Drug Administration for Xifaxan 550 mg for the treatment of IBS-D in adults.

28 May 2015

Ardelyx reports positive results from tenapanor Phase 2b clinical trial in IBS-C patients

Ardelyx, Inc., a clinical-stage biopharmaceutical company focused on cardio-renal, gastrointestinal, and metabolic diseases, today presented Phase 2b clinical trial results that demonstrated statistically significant and clinically meaningful improvement in IBS-C symptoms for tenapanor-treated patients compared to patients receiving placebo.

19 May 2015

Live, multi-strain probiotic drink may benefit people with ulcerative colitis

People with ulcerative colitis may benefit from taking the live, multi-strain probiotic drink, Symprove, to reduce intestinal inflammation, according to the results of a new study presented today at Digestive Disease Week 2015.

18 May 2015

Commonwealth announces availability of new ELISA-based blood test to quickly and reliably diagnose IBS

Commonwealth Laboratories, Inc. announced today the availability of IBSchek, a new blood test designed to help physicians quickly and reliably diagnose Irritable Bowel Syndrome (IBS).

15 May 2015

Simple blood tests diagnose irritable bowel syndrome quickly and accurately

Millions of people afflicted by irritable bowel syndrome can now be diagnosed quickly and accurately with two simple blood tests developed by a Cedars-Sinai gastroenterologist.

14 May 2015

Relaxation response has significant impact on patients with gastrointestinal disorders

A pilot study has found that participating in a nine-week training program including elicitation of the relaxation response had a significant impact on clinical symptoms of the gastrointestinal disorders irritable bowel syndrome and inflammatory bowel disease and on the expression of genes related to inflammation and the body's response to stress.

6 May 2015

New CU-Boulder study finds that hazardous drinking behaviors increase mortality rates

A new University of Colorado Boulder study involving some 40,000 people indicates that social and psychological problems caused by drinking generally trump physically hazardous drinking behaviors when it comes to overall mortality rates.

29 Apr 2015

Preclinical data from Synthetic Biologics' SYN-005 for Pertussis treatment presented at ECCMID 2015

Synthetic Biologics, Inc., a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome, announced that preclinical data from its novel SYN-005 program for the treatment of Pertussis were presented in two posters at ECCMID 2015 (European Congress of Clinical Microbiology and Infectious Diseases), on April 25, 2015, in Copenhagen, Denmark.

27 Apr 2015

Synthetic Biologics begins SYN-004 Phase 2a clinical trial to prevent C. difficile infection

Synthetic Biologics, Inc., a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome, today announced the initiation of a Phase 2a clinical trial to evaluate the gastrointestinal (GI) antibiotic-degrading effects and the safety of SYN-004, the Company's investigational oral beta-lactamase enzyme designed to protect the microbiome and prevent C. difficile infection (CDI).

30 Mar 2015

The Medical Minute highlights risk and symptoms of IBD in children

Occasional stomach aches are part of life. But when they continue for more than a few weeks, come back often or are accompanied by bloody stools and additional symptoms, the cause could be inflammatory bowel disease, or IBD.

13 Mar 2015

AGA receives gift to support young investigators advance into neuroenteric disease research

The American Gastroenterological Association Research Foundation has received a generous gift from prominent San Francisco philanthropist Athena Blackburn, which will create new research opportunities for young investigators who are interested in neuroenteric disease.

26 Feb 2015

Actavis provides overview of standalone global pharmaceutical development pipeline

Actavis plc, during its Investor Meeting in New York, today provided a detailed look into its standalone global pharmaceutical development pipeline that supports the Company's long-term organic growth. The Company provided details regarding key development programs, including clinical data, development milestones and an overview of potential market opportunities, as well as an updated look at Actavis' world-class generics pipeline, which continues to hold an industry-leading position in First-to-File opportunities in the U.S.

18 Feb 2015

New AGA guidelines provide guidance on IBS treatments

Up to 15 percent of the general adult population is affected by irritable bowel syndrome (IBS), and most patients struggle to find effective drug therapy. A new guideline from the American Gastroenterological Association provides these patients and their physician's guidance.

6 Nov 2014

Gastroenteropancreatic neuroendocrine tumors: an interview with Dr. Alexandria Phan

GEP-NETs stands for gastroenteropancreatic (GEP) neuroendocrine tumors (NETs). This is a type of rare cancer that is increasing in incidence and prevalence – more on this later.

22 Oct 2014

UB study: Males with IBS experience more interpersonal difficulties than females

One of the few studies to examine gender differences among patients with irritable bowel syndrome (IBS) has found that males with the condition experience more interpersonal difficulties than do females with the condition.

21 Oct 2014

Obeticholic acid drug shows promise against bile acid diarrhoea

A pilot study testing a new type of drug in patients with chronic diarrhoea has shown promising effects on reducing their symptoms.

21 Oct 2014

Depression contributes to abnormal pain processes in IBS patients

High rates of anxiety and depression amongst patients with irritable bowel syndrome (IBS) have led many researchers to believe there could be a causal relationship between psychological factors and IBS symptoms. Now, scientists in Germany have found clear evidence that patients with IBS process pain signals from the gut abnormally, and that disturbed brain responses to pain are particularly pronounced in patients with more depression symptoms.

3 Oct 2014

Ardelyx announces positive Phase 2b results for tenapanor in IBS-C patients

Ardelyx, Inc., a clinical-stage biopharmaceutical company focused on cardio-renal, gastrointestinal and metabolic diseases, today announced positive results from its 371 patient Phase 2b clinical trial evaluating tenapanor in patients with constipation-predominant irritable bowel syndrome (IBS-C).

1 Oct 2014

Intimate partner violence may trigger irritable bowel syndrome, insomnia

One in five men in the U.S. reports violence towards their spouse or significant other, says a new nationally-representative study by the University of Michigan.

16 Sep 2014